Navigation Links
Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
Date:5/23/2008

SUNRISE, Fla., May 23 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) announced that on May 21, 2008 it received a letter from the Nasdaq Stock Market (the "Nasdaq Letter") advising that, for the last 10 consecutive trading days, the Company's market value of listed securities had been below the minimum $50,000,000 requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Marketplace Rule 4450(b)(1)(A). Furthermore, Nasdaq stated that the Company does not comply with Nasdaq Marketplace Rule 4450(b)(1)(B), which requires the Company to have total assets and total revenue of $50,000,000 each for the most recently completed fiscal year or two of the last three most recently completed fiscal years. Compliance with either Nasdaq Marketplace Rule 4450(b)(1)(A) or 4450(b)(1)(B) is one of the minimum standards for continued inclusion on The Nasdaq Global Market.

In the Nasdaq Letter, Nasdaq advised that, in accordance with Nasdaq Marketplace Rule 4450(e)(4), the Company will be provided 30 calendar days, or until June 20, 2008 (the "Compliance Period"), to regain compliance with Nasdaq Marketplace Rule 4450(b)(1)(A).

In the event the Company determines that it is unable to regain compliance with Nasdaq Marketplace Rule 4450(b)(1)(A) during the Compliance Period, the Company intends to apply to transfer its common stock to the Nasdaq Capital Market on or before the end of the Compliance Period to seek to ensure that consistent and continual access to capital markets is maintained for all its shareholders. The Nasdaq Capital Market currently includes over 500 companies and operates in substantially the same manner as the Nasdaq Global Market. Securities listed on the Nasdaq Capital Market satisfy all applicable qualification requirements for Nasdaq securities and all companies listed on the Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq's corporate governance standards.

About Bio
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
2. Bioheart, Inc. Announces Financial Results for First Quarter 2008
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...v.25/PRNewswire/--Reportlinker.comannouncesthatane..., BrazilBioethanolMarketAnalysisandForecaststo2...razil-Bioethanol-Market-Analysis-and-Forecasts-to-...Forecaststo2013 ,, Summary ,, Thereportpro...anolmarketandtheBrazilbioethanolmarketinparticular...
(Date:11/24/2009)... The New York investment bank KTA Capital,s...greed an AU$6.7 mil convertible note private place...te placement was arranged by KTA Capital as Neuren... New York (PRWEB) November 23, 2...A Capital, LLC ("KTA Capital") has annou...
(Date:11/24/2009)... Health care employment grew by 29,000 jo...to show consistent growth during the U.S. recessio... in trouble, and health systems are coming closer ...ad of just administrators. , ...yment continued growing in October despite the she...
(Date:11/24/2009)...v.24/PRNewswire/--BlueMarbleEnergyCorp.announcedto...ority(OPDA)wererecentlyawarded$2millionbyWashingto...inaprivate/publicpartnershiptoconstructthestate,sf...,WA. ,, "Thisinvestmentwillsignificantlyspeedth...stoLincolnCounty,"saidBlueMarbleEnergyCEOKellyOgil...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...d.,(TASE: ITGI) announced today the first commerci...ardium Covered Stent (PCS) in the UK, Over and Un... tissue,designed to set a barrier between the coro...ed for situations such as degenerated Saphenous Ve...first Over and Under(R) PCS commercial implantatio...
...affect patient response to ...2 Roche and DxS Ltd. have,signed an exclusive dis...Mutation Test and TheraScreen EGFR 29 Mutation Tes...her clinically relevant factors, to aid,doctors in...rom a specific,cancer therapy based on their mutat...
...s,area within SAFC(R), a member of the Sigma-Aldri...oduction of the OM700, a bubbler that offers,custo... precursor delivery,for larger lot sizes, enabling...creased safety controls., The OM700 offers reliab...tive organometallic precursors, such as trimethylg...
Other Biology Technology:Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability 2Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 2Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 3SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 2SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 3
(Date:11/26/2009)...t in eight European countries has shown that closi...andemic could have a significant role in reducing ...pen access journal BMC Infectious Diseases compa... weekends/holidays, finding that they were reduced...t and Antwerp University, Belgium, led a team of E...
(Date:11/25/2009)...produced in the stomach, may be used to boost resi... disease, Yale School of Medicine researchers repo...Journal of Neuroscience . , Parkinson,s disease ... an area of the midbrain known as the substantia n.... Reduced production of dopamine in late-stage Pa...
(Date:11/25/2009)...a lifetime, the heart pumps some 250 million liter...is, the muscle fibers of the heart have to be extr...lfgang Rottbauer, vice chair of the Department of ...airman: Prof. Dr. H. A. Katus), has discovered a p...e smallest muscular unit, the sarcomere. In cooper...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2SYGNIS to Present at the 11th Rodman 26 Renshaw Annual Global Investment Conference 56338 1SYGNIS to Present at the 11th Rodman 26 Renshaw Annual Global Investment Conference 56338 2OAG Releases Prototype for Pandemic Disease Planning and Management 56336 1OAG Releases Prototype for Pandemic Disease Planning and Management 56336 2OAG Releases Prototype for Pandemic Disease Planning and Management 56336 3Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 1Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 2Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 3
... Department of Energys Office of Science today rel...publication, Facilities for the Future of Science:...made significant progress in deploying the scienti...tes needs to capture world scientific leadership, ...partments missions. , When it was published four ...
...One of the World,s Leading Software ..., Oct. 10 (OTC Bulletin,Board: CICI) Communicatio...lier of electronic signature solutions for busines... the recognized leader in biometric signature,veri...rd time in Software,Magazine,s Software 500 rankin...
...angladesh finds that folic acid supplements can dr...ls chronically exposed to arsenic-contaminated dri...aturally present in some soils and water. Arsenic...icant public health problem in at least 70 countri...o parts of the United States. Chronic arsenic exp...
Other Biology News:DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 2DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 3DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 4DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 5CIC Again Named to Software Magazine's Annual Prestigious Software 500 List 2CIC Again Named to Software Magazine's Annual Prestigious Software 500 List 3Folic acid lowers blood arsenic levels in Bangladesh 2Folic acid lowers blood arsenic levels in Bangladesh 3
Mouse Anti-Human XPC Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Rabbit Anti-Lck, phospho (Tyr192) Polyclonal Antibody, Unconjugated from Abcam
Anti-7H6 Antigen (tight-junction associated protein antigen) Monoclonal Antibody, Unconjugated, Clone 7H6 from Cell Sciences
Goat Anti-Ephrin B2 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: